Key Financial Figures - Q4 FY26 Performance

Revenue Performance:

  • Q4 FY26 Revenue: ₹1,139.93 lacs
  • Q4 FY25 Revenue: ₹1,232.44 lacs
  • Year-over-year change: 8% degrowth

Profitability Metrics:

  • Q4 FY26 EBITDA: ₹36.93 lacs
  • Q4 FY25 EBITDA: ₹113.94 lacs
  • Year-over-year change: 68% decrease
  • Q4 FY26 EBITDA Margin: 3.24%
  • Q4 FY25 EBITDA Margin: 9.25%
  • Q4 FY26 PBT: ₹20.97 lacs
  • Q4 FY25 PBT: ₹96.83 lacs
  • Year-over-year change: 78% decrease
  • Q4 FY26 Reported PAT: ₹10.1 lacs
  • Q4 FY25 Reported PAT: -₹339.14 lacs (loss)
  • Year-over-year change: 103% improvement
  • Q4 FY26 PAT Margin: 0.89%
  • Q4 FY25 PAT Margin: -27.52%

Other Financial Metrics:

  • Q4 FY26 Cash Profit: ₹23.53 lacs
  • Q4 FY25 Cash Profit: -₹328.89 lacs
  • Year-over-year change: 107% improvement
  • Q4 FY26 Cash Profit (%): 2.06%
  • Q4 FY25 Cash Profit (%): -26.69%
  • Q4 FY26 EPS: ₹0.13
  • Q4 FY25 EPS: -₹4.57

Key Financial Figures - Full Year FY26 Performance

Annual Performance:

  • FY26 Revenue: ₹4,747 lacs (implied from presentation)
  • FY25 Revenue: Not explicitly stated but implied 5% decline from FY26 figure
  • FY26 EBITDA: ₹363.45 lacs
  • FY25 EBITDA: ₹419.04 lacs
  • Year-over-year change: 13% decrease
  • FY26 EBITDA Margin: 7.66%
  • FY25 EBITDA Margin: 8.35%
  • FY26 Reported PAT: ₹220.17 lacs
  • FY25 Reported PAT: -₹97.87 lacs (loss)
  • Year-over-year change: 325% improvement
  • FY26 PAT Margin: 4.64%
  • FY25 PAT Margin: -1.95%
  • FY26 Cash Profit: ₹262.44 lacs
  • FY25 Cash Profit: -₹59.41 lacs
  • Year-over-year change: 542% improvement
  • FY26 Cash Profit (%): 5.53%
  • FY25 Cash Profit (%): -1.18%

Management Commentary

Strategic Focus: FY26 was described as "a year of strengthening the Company's fundamentals and improving the quality of earnings." The strategic focus remained on improving profitability, enhancing operational efficiency, and building a stronger financial foundation.

Financial Strengthening: Net Worth strengthened by over 50% during the year, supported by improved earnings and a stronger capital structure. The Company maintained prudent financial discipline, resulting in lower finance costs, improved liquidity, and positive operating cash generation.

Q4 Performance: The fourth quarter was described as "relatively challenging" but concluded with a positive PAT, reflecting the resilience of the business and benefits of structural improvements implemented over the past year.

Core Initiatives: The company focused on strengthening brand equity, improving field productivity, enhancing operating efficiencies, and maintaining financial discipline throughout FY26.

Business Operations Overview

Brand Portfolio:

  • 8 leading brands in therapeutic areas including Paediatrics, Gynaecology, Orthopaedics, and General Medicine
  • 134 products across acute and chronic segments

Human Resources:

  • 240+ team members
  • 150 Medical Representatives

Market Reach:

  • Relationships with 32,706 medical practitioners and 30,074 chemists
  • Presence in 13 states and 224 districts across India
  • 385 stockists ensuring market availability
  • Established strength in Northern and Western regions and Central India

Forward-Looking Statements

The presentation contains forward-looking statements concerning future business prospects and profitability, subject to several risks and uncertainties including earnings fluctuations, growth management, competition, economic growth in India, ability to attract professionals, time and cost overruns, government policies and actions, and fiscal policies. The company does not undertake to update these statements.